Updated:
GYRE Therapeutics
GYRE Therapeutics is a clinical-stage biotech targeting fibrotic and inflammatory diseases through a multi-tyrosine kinase inhibitor platform.
GYRE Therapeutics
GYRE Therapeutics is a clinical-stage biotechnology company focused on developing therapies for fibrotic and inflammatory diseases. The company's approach centers on targeting the underlying pathogenic mechanisms of conditions such as idiopathic pulmonary fibrosis and systemic sclerosis. GYRE's pipeline is built around its multi-targeted tyrosine kinase inhibitor platform, which aims to address the complex biology of fibrosis at its core. GYRE's lead candidate is designed to inhibit multiple kinases implicated in fibrosis progression. The company has advanced its compound through early clinical trials, generating data to support further development in pulmonary fibrosis. The geographic focus of GYRE's operations spans the United States and China, where it maintains a research and development footprint to leverage cross-border expertise in drug development and clinical trial execution. GYRE Therapeutics was established to bridge innovation in fibrosis biology with clinical application, assembling a team with experience in kinase biology and drug development. The company's pipeline strategy integrates preclinical research with targeted clinical indications, aiming to produce differentiated therapies for underserved patient populations. A structural differentiator for GYRE is its dual-region operating model, which combines U.S.-based drug discovery expertise with China-based clinical development and manufacturing capabilities, a hybrid structure designed to accelerate timelines and reduce capital intensity relative to single-region biotech firms.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is GYRE Therapeutics' lead therapeutic candidate targeting?
GYRE Therapeutics is developing a multi-targeted tyrosine kinase inhibitor designed to interrupt several pathogenic pathways involved in fibrosis. The lead candidate is being studied primarily for idiopathic pulmonary fibrosis, a progressive lung disease with limited treatment options. The compound's design aims to simultaneously inhibit multiple kinases believed to drive the fibrotic process, offering a potentially differentiated mechanism of action.
How is GYRE Therapeutics' cross-border structure organized?
GYRE maintains operational hubs in both the United States and China, a dual-region model within the biopharmaceutical sector. This structure typically supports preclinical and early clinical strategy from the U.S. arm while leveraging its China-based operations for later-stage clinical development, regulatory engagement, and manufacturing scale-up. The approach is designed to balance innovation velocity with cost efficiency.
Is GYRE Therapeutics a publicly traded company?
No, GYRE Therapeutics operates as a privately held clinical-stage biotechnology company. Without public market obligations, the firm has not disclosed detailed investor lists or funding round specifics as part of routine regulatory filings. The private structure dictates a different cadence and audience for its data disclosures compared to publicly listed biotech peers.
Which diseases does GYRE Therapeutics target in its pipeline?
GYRE's pipeline concentrates on chronic fibrotic and inflammatory diseases, with a primary clinical focus on idiopathic pulmonary fibrosis. The company is also exploring potential applications in other conditions driven by similar pathogenic pathways, such as certain forms of systemic sclerosis. By targeting core kinase pathways, GYRE aims to pursue indications characterized by high unmet medical need and shared underlying biology.
What distinguishes GYRE's approach to fibrosis from existing treatments?
Existing antifibrotic therapies for conditions like idiopathic pulmonary fibrosis slow disease progression but do not halt or reverse it. GYRE's multi-kinase inhibition strategy is designed to address the redundancy of fibrotic signaling pathways by targeting several of them concurrently. This approach reflects the biological complexity of fibrosis, where multiple overlapping signals contribute to tissue scarring, a challenge that single-target drugs have struggled to overcome.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: